The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.

Heather L Gelhorn Beatrice OsumiliKatelyn BrownMelissa M RossAndrea SchulzGabriela FernandezKristina S Boye

Published in: Patient preference and adherence (2023)

HbA1c reduction, frequency of hypoglycemia, and weight reduction are key drivers of preferences among people with T2D when considering medication options. Overall, people with T2D are likely to prefer the tirzepatide over the semaglutide 1mg medication profiles.

Keyphrases

weight loss
adverse drug
healthcare
bariatric surgery
type diabetes
roux en y gastric bypass
body mass index
physical activity
decision making
skeletal muscle
metabolic syndrome
adipose tissue